- Home
- CGC vs ADCT Comparison
CGC vs ADCT Comparison
Compare CGC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGC | ADCT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 431.2M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CGC | ADCT |
|---|---|---|
| Price | $0.95 | $1.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | ★ 7.0M | 3.1M |
| Earning Date | 05-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.17 | 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | $12,759,000.00 | ★ $81,357,000.00 |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $15.68 | $66.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.84 | $0.78 |
| 52 Week High | $2.38 | $4.98 |
Technical Indicators
Market Signals| Indicator | CGC | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 35.85 | 22.25 |
| Support Level | $0.84 | $0.78 |
| Resistance Level | $1.13 | $4.77 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 5.44 | 15.43 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).